Graham Capital Management’s ImmunityBio IBRX Stock Holding History

Graham Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-42,133	Closed	-$83.4K	–	1336
2025 Q4	$83.4K	Buy	+42,133	New	+$95.5K	﹤0.01%	1152

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Graham Capital Management's IBRX Position: Q1 2026 in Review

Graham Capital Management sold out of ImmunityBio (IBRX) in Q1 2026, closing a stake of 42,133 shares — an estimated $83.4K sold.

Graham Capital Management first reported a position in IBRX in Q4 2025 and held it in 1 quarter. The position peaked at $83.4K in Q4 2025. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

Graham Capital Management reported no remaining ImmunityBio position as of Q1 2026 after selling out during the quarter.
Graham Capital Management sold 42,133 ImmunityBio shares in Q1 2026, an estimated $83.4K.
Graham Capital Management first reported a position in ImmunityBio in Q4 2025 and held it in 1 quarter.
Graham Capital Management's ImmunityBio position peaked at $83.4K in Q4 2025.
386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.